CN108066439A - A kind of preparation method of the reducing blood lipid native compound group based on solution fermentation - Google Patents
A kind of preparation method of the reducing blood lipid native compound group based on solution fermentation Download PDFInfo
- Publication number
- CN108066439A CN108066439A CN201711412642.2A CN201711412642A CN108066439A CN 108066439 A CN108066439 A CN 108066439A CN 201711412642 A CN201711412642 A CN 201711412642A CN 108066439 A CN108066439 A CN 108066439A
- Authority
- CN
- China
- Prior art keywords
- fermentation
- liquid
- compound group
- native compound
- reducing blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 78
- 230000004151 fermentation Effects 0.000 title claims abstract description 78
- 239000008280 blood Substances 0.000 title claims abstract description 30
- 210000004369 blood Anatomy 0.000 title claims abstract description 30
- 150000001875 compounds Chemical group 0.000 title claims abstract description 29
- 150000002632 lipids Chemical class 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 62
- 239000000843 powder Substances 0.000 claims abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 27
- 241000031003 Monascus ruber Species 0.000 claims abstract description 26
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- CAXNYFPECZCGFK-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylacetonitrile Chemical compound C=1C=CC=NC=1C(C#N)C1=CC=CC=C1 CAXNYFPECZCGFK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 229940100486 rice starch Drugs 0.000 claims abstract description 9
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000012530 fluid Substances 0.000 claims abstract description 7
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 6
- 239000007921 spray Substances 0.000 claims abstract description 5
- 229930003944 flavone Natural products 0.000 claims abstract description 4
- 150000002213 flavones Chemical class 0.000 claims abstract description 4
- 235000011949 flavones Nutrition 0.000 claims abstract description 4
- 150000007524 organic acids Chemical class 0.000 claims abstract description 4
- 241001092040 Crataegus Species 0.000 claims description 19
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 19
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 19
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 19
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 19
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 19
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 19
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 19
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 19
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 19
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 19
- 244000197580 Poria cocos Species 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 238000009423 ventilation Methods 0.000 claims description 4
- 239000002028 Biomass Substances 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000007836 KH2PO4 Substances 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical class [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 235000019837 monoammonium phosphate Nutrition 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 229940026314 red yeast rice Drugs 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 150000003648 triterpenes Chemical class 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- 239000011686 zinc sulphate Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052564 epsomite Inorganic materials 0.000 claims description 2
- 235000021050 feed intake Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 229940066779 peptones Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 7
- 230000035622 drinking Effects 0.000 abstract description 5
- 235000008216 herbs Nutrition 0.000 abstract description 5
- 230000010354 integration Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 3
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000020717 hawthorn extract Nutrition 0.000 abstract 1
- 230000003516 hyperlipidaemic effect Effects 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- -1 triterpene compound Chemical class 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 241000233866 Fungi Species 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 241000282461 Canis lupus Species 0.000 description 1
- 241000657480 Crataegus pinnatifida Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of preparation methods of the reducing blood lipid native compound group based on solution fermentation, the invention discloses monascus rubers and the fermentation raw materials such as haw thorn extract, tuckahoe extracts, dusty yeast, rice starch, soyabean protein powder to be mixed in a certain ratio, after liquid state fermentation method fermentation a period of time, collect zymotic fluid, take certain method handle after and be spray dried to fine powder.Native compound group prepared by the present invention derives from " integration of drinking and medicinal herbs " raw material, containing various actives substances such as Monacolin K, flavones, triterpene compound, the organic acids that can reduce blood fat, effect with good reduction hyperlipemic patients blood fat, is both that food has higher medicinal and health value again.
Description
Technical field
The present invention relates to the preparation methods of the native compound group of integration of drinking and medicinal herbs a kind of, and in particular to one kind is sent out based on liquid
The preparation method of the reducing blood lipid native compound group of ferment method.
Background technology
Fast development and living-pattern preservation with Chinese society economy, nutrition and the health status of resident are in fast
Fast transition period.In the past 20 years, cereal (mainly coarse food grain) intake of China resident is reduced rapidly, the intake of animal food
Amount sharply increases；From the 1990s mid-term, adult is overweight to accelerate growth trend with fat present.According to national health family planning
Entrust what prevention and control of diseases office announced《Chinese residents nourishment and chronic disease status report (2015)》It has been shown that, 18 years old 2012 and with
The dyslipidemia incidence of upper adult is 40.4%, is also the risk factor for inducing cardiovascular disease.Research can reduce high blood
Fat and the native compound with integration of drinking and medicinal herbs property, can safely and effectively control blood fat, auxiliary treatment chronic disease, for ensuring
Population of China health, control cardiovascular disease incidence are extremely important.
Poria cocos Poria cocos (Schw.) Wolf. is that Polyporaceae crouches the dry sclerotia of Pseudomonas fungi, have strengthening spleen and middle warmer,
Mental-tranquilization, clearing damp and promoting diuresis function；The ingredients such as pachymaran, triterpenoid saponin have good reduction hyperlipidemia effect.Hawthorn is
The dry mature fruit of rosaceous plant hawthorn Crataegus pinnatifida Bge can help digestion and lead product, promoting blood circulation to remove blood stasis；Mountain
Flavones, triterpene, organic acid ingredient have effect for reducing fat in short, bristly hair or beard, and prevention hyperlipidemia has definite curative effect.Both of the above belongs to
Integration of drinking and medicinal herbs class raw material as defined in planning commission is defended in country.Red yeast rice is the traditional food and medicament dual-purpose fermented product in China, by monascus
Category fungi is inoculated in rice fermentation and forms, and is a kind of traditional Chinese medicine with both diet and nutrition；Monascus ruber is also in food officina of country regulation
's《The fungi strain list of health food》In.Energy metabolism generates the chemical combination such as Monacolin K to monascus ruber during the fermentation
Object has good reduction cholesterol effect, evident in efficacy, toxic side effect is small, better tolerance.
Therefore, how using Poria cocos, hawthorn, monascus ruber a kind of native compound group for reducing hyperlipidemia is prepared,
Comprehensive Poria cocos, hawthorn, the effectiveness of monascus ruber, safely and effectively control blood fat, auxiliary treatment chronic disease, are that the present invention needs to solve
The problem of.
The content of the invention
It is natural to provide a kind of reducing blood lipid based on liquid fermentation method for technical problem in the prior art by the present invention
The preparation method of compound group filters out hawthorn, Poria cocos, red yeast rice etc. in the Chinese Traditional Medicine for using more than more than one thousand years, uses
Modern liquid fermentation technology prepares a kind of native compound group that can be used for reducing hyperlipidemia, can be extensive as a kind of raw material
For health food.
The technical solution that the present invention solves above-mentioned technical problem is as follows：A kind of reducing blood lipid based on solution fermentation is naturally changed
The preparation method of object group is closed, is comprised the following steps：
Hawthorn, tuckahoe extracts are prepared, and Chinese medical extract dry powder is prepared using the hawthorn, tuckahoe extracts；
The Chinese medical extract dry powder and dusty yeast, rice starch, soyabean protein powder etc. are mixed in a certain ratio；
Monascus ruber is added in, carries out liquid state fermentation processing；
Spray drying obtains reducing blood lipid native compound group.
Further, the preparation hawthorn, tuckahoe extracts, and prepare Chinese medicine using the hawthorn, tuckahoe extracts and carry
Object dry powder is taken, including：
By hawthorn, Poria cocos medicinal material in mass ratio 1：1 mixing, coarse crushing；
Coarse powder after sieve and deionized water are pressed into mass volume ratio 1：8~1：10 mixing, cold soaking after 30 minutes, boil by heating
And it when keeping slightly boiling extraction 1~1.5 small, filters while hot；
Residue presses mass volume ratio 1 again after filter：6~1：8 ratio adds in ionized water mixing, and heating boils and keeps slightly boiling
When extraction 0.75~1 is small, filter while hot；
Filtrate is collected, is concentrated under reduced pressure into paste, density 1.10-1.30g/cm3；
Extract cream is dried under reduced pressure into dry cream, and is crushed into powder, obtains Chinese medical extract dry powder；And its quality is weighed,
And crude drug quality is converted to, it is spare.
Further, the monascus ruber is trained before liquid fermentation fermentor is entered by fermented and cultured, the monascus ruber
Support base composition：70-100g/L glucose, 0.01-0.02g/L peptones, 0.002-0.003g/L ammonium dihydrogen phosphates, 0.0004-
0.0006g/L epsom salts, 0.0001-0.0002g/L calcium chloride adjust pH to 4.8-5.0, and purified water is settled to certain body
Product, sterilizes 15-30 minutes under 121 DEG C, 0.1Mpa pressure；By monascus ruber culture transferring in monascus ruber culture medium, in biology
It is cultivated in constant-temperature shaking incubator；The control of shaking table temperature is at 30-35 DEG C, and shaking table speed control is at 160-200 revs/min, hair
Ferment time control is when 16-24 is small；Using Mycelium growth rate as reference, every milliliter of culture solution miospore number is recorded, and in
Optical microphotograph Microscopic observation mycelia bulk concentration, control described in original bacteria liquid it is mycelial conversion concentration for 5.0-8.0 × 102 plant/
Milliliter, obtains monascus ruber original bacteria liquid.
Further, it is described to compare the Chinese medical extract dry powder and dusty yeast, rice starch, soyabean protein powder by certain
Example mixing, including：
Purified water is added in after being mixed in a certain ratio, and is stirred evenly using homogeneous emulsifying machine；80 DEG C of temperature of charge, stirring
Speed >=3000 rev/min, mixing time are 15-30 minutes, and magma is made；
It is basic to calculate using liquid fermentation volume, subject to the addition dry biomass in every 100 milliliters of water, medicinal substances extract
Dry powder is to be converted to crude drug quality 2.5-3%；The dusty yeast of protein content >=50%：3%-3.5%；Rice starch：
0.8-1.2%；Soyabean protein powder：2.0-2.5%；NaNO3:0.18-0.22%；MgSO4·7H2O:0.08-0.12%；
KH2PO4:0.18-0.22%；ZnSO4·7H2O:0.34-0.38%.
Further, the magma is added in into purified water dilution, is stirred in fermentation tank, and using newborn acid for adjusting pH value, stirred
It mixes and uniformly causes 4.9-5.1；To medium sterilization, 123 DEG C of temperature, sterilization time 30-45min obtains liquid state fermentation base.
Further, the carry out liquid state fermentation processing, including：After liquid state fermentation base is cooled to room temperature, by volume
1:100~3:100 ratio adds in the monascus ruber original bacteria liquid, obtains mixed liquid state fermentation liquid.
Further, the liquid state fermentation liquid is carried out fermenting under the conditions of liquid in fermentation tank；During fermentation, according to fermentation
Liquid dissolved oxygen data regulate and control：
A) filtrated air enters the flow velocity in tank；
B) each independent paddle is fast for double paddles in fermentation tank.
Specifically, described regulate and control according to zymotic fluid dissolved oxygen data, including：
According to the growth characteristic of monascus ruber, during fermentation, the dissolved oxygen concentration that sensor is measured in fermentation tank should be controlled
System is 20%~30%；
Liquid state fermentation is divided into 2 stages progress：Cell growth stage and the stage of biological metabolite biosynthesis：
Wherein, the control of first stage temperature is at 30-32 DEG C；For the control of agitating paddle speed in 230-250r/min, upper paddle speed should
A little higher than decrease speed 5-10r/min；Throughput 1-3wm, WM represent the ratio of minute ventilation volume and the actual material liquid volume of tank body
Value adjusts throughput according to dissolved oxygen concentration；
Second stage, temperature are controlled at 22-25 DEG C；In 190-210r/min, upper and lower paddle speed is identical for agitating paddle speed control；
Throughput 1-3wm adjusts throughput according to dissolved oxygen concentration；
At 2-4 days, second stage was controlled at 4-8 days liquid state fermentation liquid first stage time control in fermentation tank.
Further, the spray drying obtains reducing blood lipid native compound group, including：The liquid state fermentation liquid, in second
Stop fermentation after stage, zymotic fluid is taken out from fermentation tank, after partial moisture is recovered under reduced pressure, it is thin to be spray dried to solid-state
Powder.
Further, according to raw material feed intake metering and existing measuring method measure Monacolin-K, flavones, triterpenes chemical combination
After the ingredients such as object, organic acid, appropriate edible adjuvant is added in proportion, prepares tablet, granule, soft capsule, pill or mouth
Take liquid.
In liquid state fermentation raw material of the present invention, integration of drinking and medicinal herbs raw material hawthorn, Poria cocos as defined in planning commission are defended including country
Extract；As defined in food officina of country《The fungi strain list of health food》In monascus ruber；And dusty yeast, rice form sediment
Powder, soyabean protein powder etc..According to the common knowledge of this field and the ingredient of auxiliary material, native compound group of the invention can be made
Various dosage forms commonly used in the art.
The various composition compound action of this native compound group realizes the effect for reducing hyperlipidemia.Classical lipidemia
Zoopery the results show that this fine powder can be substantially reduced high lipid food raising mouse dyslipidemia, have good anti-height
Blood fat.
Specific embodiment
The principle of the present invention and feature are described below in conjunction with example, the given examples are served only to explain the present invention, and
It is non-to be used to limit the scope of the present invention.
Embodiment 1
By hawthorn, Poria cocos medicinal material in mass ratio 1：4 mesh sieves are crossed in 1 mixing, coarse crushing, are weighed.By the raw material after sieve and go from
Sub- water, by 1：8 (quality：Volume) it mixes, cold soaking when heating boils and keeps slightly boiling extraction 1 small, filters while hot after 30 minutes；
Residue adds deionized water by 1 after filter：8 mixing when heating boils and keeps slightly boiling extraction 0.75 small, are filtered while hot.It collects
Filtrate decompression is condensed into paste, density 1.10-1.30g/cm by filtrate3.Extract cream is dried under reduced pressure into dry cream, and powder
Powder is broken into, and weighs its quality, and is converted to crude drug quality, spare, wherein hawthorn, Poria cocos mixing medicinal material dry extract go out cream
Rate is 21.3%.
Prepare monascus ruber culture medium：It is calculated by 1L, takes glucose 80g, peptone 0.015g, ammonium dihydrogen phosphate 0.0026g,
Epsom salt 0.0005g, calcium chloride 0.00015g purified waters are settled to 1L, and sterilize 15-30 under 121 DEG C, 0.1Mpa pressure
Minute.It is cooled to room temperature.
Monascus ruber Spawn incubation：By monascus specie culture transferring in monascus ruber culture medium, shaken in biological temperature-constant culture
It is cultivated in bed；The control of shaking table temperature is at 32 DEG C, and shaking table speed control is at 170 revs/min, when fermentation 18 is small.Fermentation ends
After record every milliliter of culture solution miospore number, survey in original bacteria liquid convert concentration be 7.2 × 102Strain/milliliter.
By solid powders such as Chinese medical extract dry powder, dusty yeast, rice starch, soyabean protein powders before liquid state fermentation, by one
Purified water is added in after certainty ratio mixing, and is stirred evenly using homogeneous emulsifying machine；Built-in temperature pre-add will be stirred before homogeneous stirring
Heat puts into material, mixing speed >=3000 rev/min to 80 DEG C, and mixing time is 15-30 minutes, and virgin pulp liquid is made.With fermentation
Tank volume is calculates basis, and subject to the addition dry biomass in every 100 milliliters of water, wherein Chinese medical extract is to be converted to active compound
Material amount 2.8%；Dusty yeast (protein content >=50%)：3.2%；Rice starch：1.0%；Soyabean protein powder：2.2%；
NaNO30.20%；MgSO4·7H2O0.10%；KH2PO40.20%；ZnSO4·7H2O 0.36%.It will stirring before homogeneous stirring
Built-in temperature is preheated to 80 DEG C, after more than material puts into homogeneous emulsifying machine, and 20 are stirred under the conditions of rotating speed is 3000 rev/min
Minute, virgin pulp liquid is made.
Liquid virgin pulp liquid is added in fermentation tank, and supplement purified water is to calculating volume and stirs evenly, and is adjusted using lactic acid
PH value stirs evenly and causes pH5.0；123 DEG C of temperature, sterilization time 30-45min sterilize.
After liquid state fermentation base after sterilizing is cooled to room temperature, monascus ruber original bacteria liquid is added in, it is molten by final liquid state fermentation base
Liquid volume ratio (2.2：100) add in.It carries out fermenting under the conditions of liquid in fermentation tank.
According to the growth characteristic of monascus ruber, the dissolved oxygen concentration that electronic nose is measured in fermentation tank should be controlled 25%.
Liquid state fermentation is divided into 2 stages progress：Cell growth stage and the stage of biological metabolite biosynthesis.Wherein, the first stage
Temperature is controlled at 30 DEG C, and time control was at 2.5 days；Agitating paddle speed control in 230-250r/min, upper paddle speed answer it is a little higher than under
Reduction of speed degree 5-10r/min；Throughput 1-3wm (WM represents minute ventilation volume and the ratio of the actual material liquid volume of tank body), according to
Dissolved oxygen concentration adjusts throughput.Second stage, at 22-25 DEG C, time control was controlled at 4-8 days for temperature control；Agitating paddle speed
In 190-210r/min, upper and lower paddle speed is identical for control；Throughput 1-3wm adjusts throughput according to dissolved oxygen concentration.The fermentation phase
Between take out sample liquid from fermentation tank daily, the metabolite based on observation monascus mycelia upgrowth situation, Monacolin-K is dense
Degree.
After terminating fermentation, zymotic fluid is taken out from fermentation tank.After partial moisture is recovered under reduced pressure, adjustment density to 1.21g/
cm3, solid fine powder is spray dried to, and quality is weighed, it is converted into corresponding spray drying fine powder 1g and contains hawthorn+Poria cocos crude drug
1.43g。
Embodiment 2
Pharmacological experiment has been selected to confirm that the reduction hyperlipidemia of the solid fine powder prepared by embodiment 1 acts on.Experiment is dynamic
Object is 50 male mouse of kunming, and 28 ± 2g of weight is randomly divided into 5 groups, i.e. gives normal group of the physiological saline of certain volume
(1), model group (2), low dose group (3), middle dose group (4) and high dose group (5)；Every group ten, 2-5 groups give drink high in fat
Food.According to pharmacopeia recommended dose, hawthorn is 9-12g/ days, and Poria cocos is 10-15g/ days, takes 10g/ days as maximum dose level group, root
According to animals and human beings body surface area than scaling method, high dose group is 2.6g/kg, and middle dose group 1.3g/kg, low dose group is suitable
In 0.65g/kg；1, No. 2 group gives physiological saline, and equal gastric infusion 1 time a day, is continuously taken 14 days.Blood was measured after 14 days
Clearing gallbladder sterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-
C).It the results are shown in Table 1.
TC, TG, LDL-C, HDL-C compare in 1 separate groups of mice blood of table
Experimental result shows that native compound group prepared by this method has good reduction blood compared with model group
The concentration of middle TC, TG, LDL-C raise HDL-C concentration, show the effect of the lipid of mice of good reduction High-fat diet
Fruit；High dose group effect is best.
Embodiment 3
Establish the method that high performance liquid chromatography measures Monacolin-K.Precision weighs the powder 0.1g of spray drying gained,
It is placed in centrifuge tube, adds in the phosphate aqueous solution of 10.0mL pH3.10.0mL chloroforms are added after ultrasonic extraction 30min,
It is placed in vortex vortex mixer mixing 15min.Remove upper strata aqueous phase after standing, chloroform layer is centrifuged into 3min with 3000r/min.Make
With C18 reverse chromatograms column (4.6mm × 250mm), column temperature is room temperature；Ultraviolet detection wavelength 238nm；Mobile phase is acetonitrile：Water：
0.5% phosphoric acid=60：37：3 (volume ratios)；Flow velocity be 1.0mL min, 10 microlitres of sample size.1 batch of Sample Spray dry is measured,
Monacolin-K contents are 1.02% (lactone formula+acid summation) in solid powder.
The foregoing is merely presently preferred embodiments of the present invention, is not intended to limit the invention, it is all the present invention spirit and
Within principle, any modifications, equivalent replacements and improvements are made should all be included in the protection scope of the present invention.
Claims (10)
1. a kind of preparation method of the reducing blood lipid native compound group based on solution fermentation, which is characterized in that including following step
Suddenly：
Hawthorn, tuckahoe extracts are prepared, and Chinese medical extract dry powder is prepared using the hawthorn, tuckahoe extracts；
The Chinese medical extract dry powder is mixed in a certain ratio and stirred evenly with dusty yeast, rice starch, soyabean protein powder；
Monascus ruber is added in, carries out liquid state fermentation processing；
Spray drying obtains reducing blood lipid native compound group.
2. a kind of preparation method of the reducing blood lipid native compound group based on solution fermentation according to claim 1, special
Sign is, the preparation hawthorn, tuckahoe extracts, and prepares Chinese medical extract dry powder using the hawthorn, tuckahoe extracts,
Including：
By hawthorn, Poria cocos medicinal material in mass ratio 1：1 mixing, coarse crushing；
Coarse powder after sieve and deionized water are pressed into mass volume ratio 1：8~1：10 mixing, cold soaking after 30 minutes, boil and protect by heating
Hold slightly boiling extraction 1~1.5 it is small when, filter while hot；
Residue presses mass volume ratio 1 again after filter：6~1：8 ratio adds in deionized water mixing, and heating boils and slightly boiling is kept to carry
Take 0.75~1 it is small when, filter while hot；
Filtrate is collected, is concentrated under reduced pressure into paste, density 1.10-1.30g/cm3；
Extract cream is dried under reduced pressure into dry cream, and is crushed into powder, obtains Chinese medical extract dry powder；And its quality is weighed, and roll over
Crude drug quality is counted as, it is spare.
3. a kind of preparation method of the reducing blood lipid native compound group based on solution fermentation according to claim 1, special
Sign is that the monascus ruber is before liquid fermentation fermentor is entered by fermented and cultured, the monascus ruber culture medium composition：
70-100g/L glucose, 0.01-0.02g/L peptones, 0.002-0.003g/L ammonium dihydrogen phosphates, 0.0004-0.0006g/L
Epsom salt, 0.0001-0.0002g/L calcium chloride adjust pH to 4.8-5.0, and purified water is settled to certain volume, in 121 DEG C,
It sterilizes 15-30 minutes under 0.1Mpa pressure；By monascus ruber culture transferring in monascus ruber culture medium, in biological temperature-constant culture shaking table
In cultivated；The control of shaking table temperature is at 30-35 DEG C, and at 160-200 revs/min, fermentation time control exists shaking table speed control
When 16-24 is small；Using Mycelium growth rate as reference, every milliliter of culture solution miospore number is recorded, and under light microscope
Mycelia bulk concentration is observed, it is 5.0-8.0 × 10 to control mycelial conversion concentration described in original bacteria liquid2Strain/milliliter obtains red yeast rice
Mould original bacteria liquid.
4. a kind of preparation method of the reducing blood lipid native compound group based on solution fermentation according to claim 3, special
Sign is, described to be mixed in a certain ratio the Chinese medical extract dry powder with dusty yeast, rice starch, soyabean protein powder,
Including：
Purified water is added in after being mixed in a certain ratio, and is stirred evenly using homogeneous emulsifying machine；80 DEG C of temperature of charge, mixing speed
>=3000 revs/min, mixing time is 15-30 minutes, and magma is made；
It is basic to calculate using liquid fermentation volume, subject to the addition dry biomass in every 100 milliliters of water, medicinal substances extract dry powder
To be converted to crude drug quality 2.5-3%；The dusty yeast of protein content >=50%：3%-3.5%；Rice starch：0.8-
1.2%；Soyabean protein powder：2.0-2.5%；NaNO3:0.18-0.22%；MgSO4·7H2O:0.08-0.12%；KH2PO4:
0.18-0.22%；ZnSO4·7H2O:0.34-0.38%.
5. a kind of preparation method of the reducing blood lipid native compound group based on solution fermentation according to claim 4, special
Sign is, further includes：The magma is added in into purified water dilution, is stirred in fermentation tank, and uses newborn acid for adjusting pH value, stirring
Uniformly cause 4.9-5.1；To medium sterilization, 123 DEG C of temperature, sterilization time 30-45min obtains liquid state fermentation base.
6. a kind of preparation method of the reducing blood lipid native compound group based on solution fermentation according to claim 5, special
Sign is, the carry out liquid state fermentation processing, including：After liquid state fermentation base is cooled to room temperature, by volume 1:100~3:
100 ratio adds in the monascus ruber original bacteria liquid, obtains mixed liquid state fermentation liquid.
7. a kind of preparation method of the reducing blood lipid native compound group based on solution fermentation according to claim 6, special
Sign is, the liquid state fermentation liquid is carried out in fermentation tank to ferment under the conditions of liquid；During fermentation, according to zymotic fluid dissolved oxygen number
According to regulation and control：
A) filtrated air enters the flow velocity in tank；
B) each independent paddle is fast for double paddles in fermentation tank.
8. a kind of preparation method of the reducing blood lipid native compound group based on solution fermentation according to claim 7, special
Sign is, described to be regulated and controled according to zymotic fluid dissolved oxygen data, including：
According to the growth characteristic of monascus ruber, during fermentation, the dissolved oxygen concentration that sensor is measured in fermentation tank should control
20%~30%；
Liquid state fermentation is divided into 2 stages progress：Cell growth stage and the stage of biological metabolite biosynthesis：
Wherein, the control of first stage temperature is at 30-32 DEG C；Agitating paddle speed is controlled in 230-250r/min, and upper paddle speed should be slightly higher
In decrease speed 5-10r/min；Throughput 1-3wm, WM represent minute ventilation volume and the ratio of the actual material liquid volume of tank body, root
Throughput is adjusted according to dissolved oxygen concentration；
Second stage, temperature are controlled at 22-25 DEG C；In 190-210r/min, upper and lower paddle speed is identical for agitating paddle speed control；Ventilation
1-3wm is measured, throughput is adjusted according to dissolved oxygen concentration；
At 2-4 days, second stage was controlled at 4-8 days liquid state fermentation liquid first stage time control in fermentation tank.
9. a kind of preparation method of the reducing blood lipid native compound group based on solution fermentation according to claim 8, special
Sign is that the spray drying obtains reducing blood lipid native compound group, including：The liquid state fermentation liquid, terminates in second stage
Stop fermentation afterwards, zymotic fluid is taken out from fermentation tank, after partial moisture is recovered under reduced pressure, is spray dried to solid fine powder.
10. a kind of preparation method of the reducing blood lipid native compound group based on solution fermentation according to claim 9, special
Sign is, further includes, according to raw material feed intake metering and existing measuring method measure Monacolin-K, flavones, triterpenes chemical combination
After the ingredients such as object, organic acid, appropriate edible adjuvant is added in proportion, prepares tablet, granule, soft capsule, pill or mouth
Take liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711412642.2A CN108066439A (en) | 2017-12-24 | 2017-12-24 | A kind of preparation method of the reducing blood lipid native compound group based on solution fermentation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711412642.2A CN108066439A (en) | 2017-12-24 | 2017-12-24 | A kind of preparation method of the reducing blood lipid native compound group based on solution fermentation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108066439A true CN108066439A (en) | 2018-05-25 |
Family
ID=62155626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711412642.2A Pending CN108066439A (en) | 2017-12-24 | 2017-12-24 | A kind of preparation method of the reducing blood lipid native compound group based on solution fermentation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108066439A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045045A (en) * | 2018-08-14 | 2018-12-21 | 淮南师范学院 | A kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease |
| CN110250380A (en) * | 2019-06-06 | 2019-09-20 | 暨南大学 | A kind of sweet potato fermented beverage and preparation method thereof with ease constipation and hypolipemic function |
-
2017
- 2017-12-24 CN CN201711412642.2A patent/CN108066439A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045045A (en) * | 2018-08-14 | 2018-12-21 | 淮南师范学院 | A kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease |
| CN110250380A (en) * | 2019-06-06 | 2019-09-20 | 暨南大学 | A kind of sweet potato fermented beverage and preparation method thereof with ease constipation and hypolipemic function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100457892C (en) | Traditional Chinese medicine solid type mixed culture fermentation tech. and its application | |
| CN105859359A (en) | Selenium-enriched foliar fertilizer for paddy rice | |
| CN105996022A (en) | Method for producing functional foods by simultaneously converting Chinese yam from cordyceps taishanensis | |
| CN107373266A (en) | A kind of rose enzyme solid beverage and its preparation technology | |
| CN106177339A (en) | A kind of method preparing treatment gout herbal formulation | |
| CN106136136A (en) | A kind of method utilizing Monascus anka Nakazawa et sato to convert Rhizoma Dioscoreae production functional food | |
| CN106174221A (en) | A kind of method utilizing Ganoderma to convert Rhizoma Dioscoreae production functional food | |
| CN109938332A (en) | A kind of Hericium erinaceus health-care preparation and preparation method thereof containing erythrothioneine | |
| CN107114758A (en) | A kind of ferment cordyceps sinensis D-mannitol powder and preparation method thereof | |
| CN106434157A (en) | Traditional Chinese medicinal distiller's yeast and preparation method | |
| CN106418525A (en) | Fermenting folium mori chewable tablet and preparation method thereof | |
| CN108066439A (en) | A kind of preparation method of the reducing blood lipid native compound group based on solution fermentation | |
| CN108185140A (en) | Pueraria lobata composite fermentation object and its preparation method and application | |
| CN104840778A (en) | Traditional Chinese medicine fermented hair-blacking preparation, preparation method and purpose thereof | |
| CN106728083A (en) | Spina date seed Poria cocos common fermentation product and its preparation method and application | |
| CN101664180A (en) | Health-care nutritional complexing agent with effect of and preparation method thereof | |
| CN116355816A (en) | Microorganism of fermented samara oil seed and blood lipid reducing composition thereof | |
| CN106421275A (en) | Traditional Chinese medicine compound preparation for treating fish sporidiosis and preparation method thereof | |
| CN1218745C (en) | Health food for protecting liver and adjusting blood fat and method for preparing the same | |
| CN109439719A (en) | A kind of fungi two-way solid-fermented technique and its application based on Cortex Eucommiae | |
| CN106754057B (en) | Health-care red yeast glutinous rice wine and preparation method thereof | |
| US6541163B1 (en) | Process of powder for bath from natural plants | |
| TW200948371A (en) | Cultivation method and liquid culture medium for cultivation of mycelium and fruiting body of Cordyceps | |
| CN108936577A (en) | A kind of compound group preparation method of the edible natural with cardiovascular protective effect | |
| CN107927366A (en) | New disease-resistant lamb supplement material of height and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180525 |